Your browser doesn't support javascript.
loading
Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course.
DiNatale, Renzo G; Gorelick, Alexander N; Makarov, Vladimir; Blum, Kyle A; Silagy, Andrew W; Freeman, Benjamin; Chowell, Diego; Marcon, Julian; Mano, Roy; Sanchez, Alex; Attalla, Kyrollis; Weng, Stanley; Voss, Martin; Motzer, Robert J; Russo, Paul; Coleman, Jonathan A; Reuter, Victor E; Chen, Ying-Bei; Chan, Timothy A; Reznik, Ed; Tickoo, Satish K; Hakimi, A Ari.
  • DiNatale RG; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan
  • Gorelick AN; Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Makarov V; Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Blum KA; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Silagy AW; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Freeman B; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Chowell D; Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Marcon J; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Mano R; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Sanchez A; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Attalla K; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Weng S; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Voss M; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Motzer RJ; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Russo P; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Coleman JA; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Reuter VE; Pathology Department, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Chen YB; Pathology Department, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Chan TA; Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Reznik E; Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Tickoo SK; Pathology Department, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: tickoos@mskcc.org.
  • Hakimi AA; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: hakimia@mskcc.org.
Eur Urol Focus ; 7(2): 381-389, 2021 03.
Article en En | MEDLINE | ID: mdl-31813809
ABSTRACT

BACKGROUND:

TCEB1-mutant renal cell carcinoma (RCC) is a rare variant of RCC with clear-cell features. Owing to its unique morphological and molecular features it has recently been proposed as a separate entity. Initial series suggested an indolent, early-stage phenotype. Here we expand our clinical cohort and describe a more detailed genomic analysis looking for potential drivers of aggressiveness. DESIGN, SETTING, AND

PARTICIPANTS:

We identified five new cases in our institutional sequencing cohort, four of whom were found to have high-stage disease (American Joint Committee on Cancer stage III/IV). Twelve previously reported cases were pooled for comparison purposes (Sato, The Cancer Genome Atlas, TRACERx Renal). OUTCOME MEASURES AND STATISTICAL

ANALYSIS:

We used our previously validated pipeline to analyze somatic mutations and copy number alterations (CNAs) in seven tumor samples with available data and estimated the number of cancer cells bearing each somatic mutation. The oncogenic potential of mutations was assessed using OncoKB and two other algorithms. Mann-Whitney U tests were used to evaluate differences in genomic markers between stage groups. RESULTS AND

LIMITATIONS:

All tumors showed biallelic inactivation of the TCEB1 gene according to a combination of somatic mutation and CNA analyses. Mutations were always found in residues involved in hydrophobic interactions with VHL. We found that high-stage tumors had additional oncogenic mutations (median 1, interquartile range [IQR] 1-1 vs 2, IQR 2-2; median difference 1, 95% confidence interval [CI] 1-1; p= 0.002) and showed whole-genome doubling events. They also seemed to have a higher burden of somatic CNAs (median fraction CNA genome 0.10, IQR 0.10-0.15 vs 0.63, IQR 0.58-0.68), however, this finding did not reach statistical significance (median difference 0.49, 95% CI 0.33-0.63; p=0.052).

CONCLUSIONS:

TCEB1-mutant RCC can show variable behavior ranging from very indolent to aggressive. Specific molecular events leading to high genomic instability seem to be associated with aggressiveness. This study expands the clinical spectrum of TCEB1-mutant RCC. PATIENT

SUMMARY:

We present four cases of aggressive TCEB1-mutant renal cell carcinoma, a rare type of kidney cancer. In-depth analysis of the genomes of these tumors revealed certain abnormalities that might explain this aggressive behavior.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article